Literature DB >> 12324562

Risks and benefits of activated protein C treatment for severe sepsis.

H Shaw Warren1, Anthony F Suffredini, Peter Q Eichacker, Robert S Munford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12324562     DOI： 10.1056/NEJMsb020574

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  52 in total

Review 1.  [Activated protein C. Inevitable in sepsis?].

Authors:  M Max
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

2.  An update on activated protein C (xigris) in the management of sepsis.

Authors:  Cesar Alaniz
Journal:  P T       Date:  2010-09

3.  Results from the National Sepsis Practice Survey: use of drotrecogin α (activated) and other therapeutic decisions.

Authors:  James M O'Brien; Scott K Aberegg; Naeem A Ali; Gregory B Diette; Stanley Lemeshow
Journal:  J Crit Care       Date:  2010-06-19       Impact factor: 3.425

4.  Evaluation of drotrecogin alpha use in a Belgian university hospital.

Authors:  Isabel Spriet; Wouter Meersseman; Alexander Wilmer; Geert Meyfroidt; Minne Casteels; Ludo Willems
Journal:  Pharm World Sci       Date:  2006-11-17

Review 5.  The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.

Authors:  T C Hall; D K Bilku; D Al-Leswas; C Horst; A R Dennison
Journal:  Ir J Med Sci       Date:  2011-11-08       Impact factor: 1.568

6.  Why are physicians so skeptical about positive randomized controlled clinical trials in critical care medicine?

Authors:  Jesús Villar; Lina Pérez-Méndez; Armando Aguirre-Jaime; Robert M Kacmarek
Journal:  Intensive Care Med       Date:  2004-11-23       Impact factor: 17.440

7.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

8.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

9.  Activated protein C: do more survive?

Authors:  Saxon Ridley
Journal:  Intensive Care Med       Date:  2006-03-01       Impact factor: 17.440

10.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.